Rapid and Simple Detection of Isoniazid-Resistant Mycobacterium tuberculosis Utilizing a DNA Chromatography-Based Technique.

Despite the availability of anti-tuberculosis drugs, the treatment of tuberculosis has been complicated by drug-resistant tuberculosis. The early detection of drug resistance makes early treatment possible. However, the available tools are mainly for rifampicin resistance detection, and the existing isoniazid resistance detection method is expensive, highly technical, and complicated, making it unsustainable for use in developing nations. This study aimed to develop a simple, rapid, and low-cost diagnostic kit for isoniazid-resistant tuberculosis using the single-stranded tag hybridization method to target an isoniazid resistance-conferring mutation. Specificity and sensitivity were assessed using DNA extracted from 49 isoniazid-resistant and 41 isoniazid-susceptible Mycobacterium tuberculosis clinical isolates cultured in mycobacterial growth indicator tubes. Positive signals were observed on mutant and wild-type lines with 100% sensitivity and specificity compared with Sanger sequencing results. In contrast, no positive signal was observed for non-tuberculosis mycobacteria. The detection limit of this method was 103 CFU or less. The STH-PAS system for isoniazid-resistant M. tuberculosis detection developed in this study offers a better alternative to conventional phenotypic isoniazid resistance determination, which will be of both clinical and epidemiological significance in resource-limited nations.

Simultaneous voltammetric determination of acetaminophen and isoniazid using MXene modified screen-printed electrode.

Determination of hepatotoxic drugs is critical for both clinical diagnosis and quantity control of their pharmaceutical formulations. In this work, a facile and sensitive sensor based on MXene modified screen-printed electrode (MXene/SPE) has been developed for detection of acetaminophen (ACOP) and isoniazid (INZ), which are two commonly used drugs but might induce liver damage in certain circumstances. MXene showed excellent electrocatalytic activity toward the oxidation of ACOP and INZ compared with bare SPE in 0.1 M H2SO4, and the separated oxidation peak potentials ensured simultaneous detection of the targets with wide linear ranges from 0.25 to 2000 µM for ACOP and 0.1-4.6 mM for INZ. The detection limits of ACOP and INZ were 0.048 µM and 0.064 mM, respectively. (S/N = 3). MXene/SPE exhibits good stability, reproducibility and repeatability, and the method has been successfully applied for detection of ACOP and INZ in their pharmaceutical and biological samples with satisfactory recovery.

An Enzyme-Induced Novel Biosensor for the Sensitive Electrochemical Determination of Isoniazid.

In this present work, a glassy carbon electrode (GCE) was modified primarily with multiwalled carbon nanotubes (MWCNTs) and a composite of MWCNTs and titanium oxide nanoparticles (TiO2NPs). The enzyme horseradish peroxidase (HRP) was immobilized to enhance the sensing ability of GCE. The proposed biosensor was used for the sensitive determination of isoniazid (INZ) in various pharmaceutical samples. The electrochemical behaviour of the developed MWCNT-TiO2NPs-HRP-GCE biosensor was studied by using cyclic voltammetry (CV) and differential pulse voltammetric (DPV) techniques. Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), thermogravimetry (TGA) and transmission electron microscopy (TEM) techniques were used to characterize the developed sensor. Phosphate buffer solution (PBS) with pH 7 was used as supporting electrolyte in the present investigation. The cyclic voltammetric results revealed that the increment of anodic peak currents for the enzyme-induced sensor was almost 8-fold greater than that of a bare GCE. The DPV technique exhibited good limit of detection and limit of quantification values, viz., 0.0335 µM and 0.1118 µM, respectively. Moreover, the developed sensor showed long-lasting stability and repeatability without any interferents. This strongly indicates that the fabricated sensor shows outstanding electrochemical performance towards INZ, with excellent selectivity and sensitivity. The developed sensor was successfully applied to pharmaceutical samples and gave good percentages of recoveries.

Potential of multisyringe chromatography for the on-line monitoring of the photocatalytic degradation of antituberculosis drugs in aqueous solution.

In this study, a multisyringe chromatography system (MSC) using a C18 monolithic column was proposed for the on-line monitoring of the photocatalytic degradation of isoniazid (INH, 10 mg L(-1)) and pyrazinamide (PYRA, 5mgL(-1)) mixtures in aqueous solution using a small sample volume (200 µL) with an on-line filtration device in a fully automated approach. During the photocatalytic oxidation using TiO2 or ZnO semiconductor materials, total organic carbon (TOC) and the formed intermediates were analyzed off-line using ion chromatography, ion exclusion HPLC, and ESI-MS/MS. The results showed that TiO2 exhibits a better photocatalytic activity than ZnO under UV irradiation (365 nm) for the degradation of INH and PYRA mixtures, generating 97% and 92% degradation, respectively. The optimal oxidation conditions were identified as pH 7 and 1.0 g L(-1) of TiO2 as catalyst. The mineralization of the initial organic compounds was confirmed by the regular decrease in TOC, which indicated 63% mineralization, and the quantitative release of nitrate and nitrite ions, which represent 33% of the nitrogen in these compounds. The major intermediates of INH degradation included isonicotinamide, isonicotinic acid, and pyridine, while the ESI-MS/MS analysis of PYRA aqueous solution after photocatalytic treatment showed the formation of pyrazin-2-ylmethanol, pyrazin-2-ol, and pyrazine. Three low-molecular weight compounds, acetamide, acetic acid and formic acid, were detected during INH and PYRA decomposition. PYRA was more resistant to photocatalytic degradation due to the presence of the pyrazine ring, which provides greater stability against OH attack.

Optimization of a reversed-phase-high-performance thin-layer chromatography method for the separation of isoniazid, ethambutol, rifampicin and pyrazinamide in fixed-dose combination antituberculosis tablets.

This paper presents the development of a new RP-HPTLC method for the separation of pyrazinamide, isoniazid, rifampicin and ethambutol in a four fixed-dose combination (4 FDC) tablet formulation. It is a single method with two steps in which after plate development pyrazinamide, isoniazid and rifampicin are detected at an UV wavelength of 280 nm. Then ethambutol is derivatized and detected at a VIS wavelength of 450 nm. Methanol, ethanol and propan-1-ol were evaluated modifiers to form alcohol-water mobile phases. Systematic optimization of the composition of each alcohol in the mobile phase was carried out using the window diagramming concept to obtain the best separation. Examination of the Rf distribution of the separated compounds showed that separation of the compounds with the mobile phase containing ethanol at the optimal fraction was almost situated within the optimal Rf-values region of 0.20-0.80. Therefore, ethanol was selected as organic modifier and the optimal mobile phase composition was found to be ethanol, water, glacial acetic acid (>99% acetic acid) and 37% ammonia solution (70/30/5/1, v/v/v/v). The method is new, quick and cheap compared to the actual method in the International Pharmacopoeia for the assay of the 4 FDC tablets, which involves the use of two separate HPLC methods.

Use of cloud point extraction with derivatizing reagent for the extraction and determination of isoniazid.

A simple and sensitive cloud point extraction high-performance liquid chromatography method is proposed for the determination of isoniazid in blood. The procedure is based on the product of the reaction of isoniazid with benzaldehyde. It can be validated that there is a linear relationship between the signal of isonicotinyl hydrazone and the concentration of isoniazid. A cloud point extraction system of nonionic surfactant Triton X-100 is applied for preconcentration of isonicotinyl hydrazone. Then the analytes in surfactant-rich phase are detected with HPLC-UV system. calibration graph was obtained in the range of 2.0 × 10(-3)-0.5 mg/L, the detection limit was 5.0 × 10(-4) mg/L. Method validation is performed on serum samples spiked at two levels, the recoveries ranging from 82.17-83.81%, with relative standard deviations from 2.45% to 3.89%.

Simple means to alleviate sensitivity loss by trifluoroacetic acid (TFA) mobile phases in the hydrophilic interaction chromatography-electrospray tandem mass spectrometric (HILIC-ESI/MS/MS) bioanalysis of basic compounds.

Trifluoroacetic acid (TFA) is a commonly used additive in HPLC and LC-MS analysis of basic compounds. It is also routinely added to aqueous-organic mobile phases utilized in the hydrophilic interaction chromatography-electrospray tandem mass spectrometry (HILIC-ESI/MS/MS) technique used in our laboratories for bioanalysis. However, TFA is known to suppress the ESI signals of analytes due to its ability to form gas-phase ion pairs with positively-charged analyte ions. The most common method to overcome this problem involves the post-column addition of a mixture of propionic acid and isopropanol. However the post-column addition setup requires additional pumps and is not desirable for continuous analysis of large amounts of samples. In this paper we present a simple yet very effective means of minimizing the negative effect of TFA in bioanalysis by direct addition of 0.5% acetic acid or 1% propionic acid to mobile phases containing either 0.025 or 0.05% TFA. A factor of two- to five-fold signal enhancement was achieved for eight basic compounds studied. Furthermore, chromatography integrity was maintained even with the addition of acetic acid and propionic acid to existing TFA mobile phases. This method has been successfully applied to the HILIC-ESI/MS/MS high-throughput analysis of extracted biological samples to support pre-clinical and clinical studies.

Chromatographic methods for the separation of biocompatible iron chelators from their synthetic precursors and iron chelates.

Chromatographic methods have been developed for the separation of the three novel biocompatible iron chelators pyridoxal isonicotinoyl hydrazone (PIH), salicylaldehyde isonicotinoyl hydrazone (SIH), and pyridoxal 2-chlorobenzoyl hydrazone (o-108) from their synthetic precursors and iron chelates. The chromatographic analyses were achieved using analytical columns packed with 5 microm Nucleosil 120-5 C18. For the evaluation of all chelators in the presence of the synthetic precursors, EDTA was added to the mobile phase at a concentration of 2 mM. The best separation of PIH and its synthetic precursors was achieved using a mixture of phosphate buffer (0.01 M NaH2PO4, 5 mM 1-heptanesulfonic acid sodium salt; pH 3.0) and methanol (55:45, v/v). For separation of SIH and its synthetic precursors, the mobile phase was composed of 0.01 M phosphate buffer (pH 6.0) and methanol (60:40, v/v). o-108 was analyzed employing a mixture of 0.01 M phosphate buffer (pH 7.0), methanol, and acetonitrile (60:20:20, v/v/v). These mobile phases were slightly modified to separate each chelator from its iron chelate. Furthermore, a RP-TLC method has also been developed for fast separation of all compounds. The chromatographic methods described herein could be applied in the evaluation of purity and stability of these drug candidates.

Resistencia de Mycobacterium tuberculosis en pacientes mexicanos. I. Características clínicas y factores de riesgo / Drug resistence of M. tuberculosis in Mexican patients: I. clinical manifestations and risk factors

Objetivo. Determinar las manifestaciones asociadas con la infección por M. tuberculosis resistente y la susceptibilidad antimicrobiana de aislados de pacientes mexicanos. Diseño. Vigilancia epidemiológica. Sitio. Centro de tercer nivel. Pacientes. Casos de tuberculosis confirmada. Mediciones. Resistencia primaria: cuando no hubo antecedente de tratamiento, y secundaria cuando lo hubo. Se emplearon las siguientes concentraciones críticas (µg/mL): son isoniacida 0.2 y 1; rifampicina 1 y 5; etambutol 5 y 10; estreptomicina 2 y 10; etionamida 5; kanamicina 6; y ácido paraaminosalicílio (PAS) 2 y 10. Resultados. Se incluyeron 84 pacientes con edad promedio de 44.7 años (6-80 años); 54 hombres (64 por ciento) y 30 mujeres (36 por ciento). La mayoría (35/62) del Distrito Federal y del Estado de México. Sólo en 34 pacientes se obtuvo información clínica: 26 presentaron fiebre y pérdida de peso, y ocho síntomas respiratorios. Se encontraron 59 pacientes (70 por ciento) con M. tuberculosis sensible y 25 resistente (30 por ciento). En 17 (68 por ciento) hubo resistencia a dos drogas y 16 (64 por ciento) de ellos a isoniacida y rifampicina. La tasa de resistencia global fue: isoniacida 24 por ciento, rifampicina 19 por ciento, estreptomicina 12 por ciento, etambutol 10 por ciento, PAS 9 por ciento, etianamida 7 por ciento y kanamicina 6 por ciento. En 47 pacientes sin tratamiento previo, ocho tuvieron infección por organismos resistentes (17 por ciento), y la tasa de resistencia primaria fue: isoniacida 9 por ciento, rifampicina 6 por ciento, estreptomicina 2 por ciento, etambutol 2 por ciento, PAS 6 por ciento y multirresistencia 6 por ciento. De 37 pacientes con tratamiento previo, 17 (46 por ciento) tuvieron un organismo resistente, y la tasa de resistencia secundaria fue: isoniacida 44 por ciento, rifampicina 35 por ciento, estreptomicina 24 por ciento, etambutol 19 por ciento, PAS 12 por ciento y multirresistencia 35 por ciento. Incluimos cuatro médicos con M. tuberculosis mono o multirresistente y siete pacientes con SIDA, uno de ellos con multirresistencia y otro con resistenia a isoniacida. Conclusión. Los resultados muestran tasas elevadas de resistencia a isoniacida y rifampicina, y de multirresistencia en M. tuberculosis aislado de pacientes mexicanos

Acetylation phenotyping of isoniazid using a simple and accurate high-performance liquid chromatography.

A simple, specific, accurate and reproducible method for the analysis of isoniazid and its major metabolite, N-acetylisoniazid in urine using high-performance liquid chromatography (HPLC) is described. The assay is performed after extraction of isoniazid, N-acetylisoniazid and 5-(4-methylphenyl)-5-phenylhydantoin (internal standard) from urine using a mixture of chloroform:isopropanol (70:30, v/v) and eluted from a 5 microns C-18 reversed phase column at ambient temperature with a mobile phase consisting of 10 mM sodium acetate:methanol:acetonitrile (40:40:20, v/v) containing 10 mM dioctylsulphosuccinate sodium and adjusted to pH 2.9 with sulphuric acid (less than 1 ml), at a flow rate of 1 ml/min with u.v. detection at 266 nm. Quantification was achieved by the measurement of the peak height ratio, and the absolute recoveries ranged from 94 to 99%. Within-day coefficients of variation ranged from 2.81 to 4.54% for isoniazid and from 2.37 to 3.75% for N-acetylisoniazid. Between-day CVs varied from 3.27 to 5.62% and from 2.5 to 4.91% for isoniazid and N-acetylisoniazid, respectively. Preliminary stability tests using a urine sample from a subject showed an increase in mean isoniazid concentration of about 25% after 1 month storage at -20 degrees C. The method was used for acetylation phenotyping of five individuals.